Finerenone Gets Expanded FDA Approval in Heart Failure

FDA approves Kerendia for heart failure with ejection fraction of 40% or higher

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

Bayer’s Blockbuster Hopeful Kerendia Expands its FDA Approval to Type of Heart Failure

The FDA approved Bayer’s Kerendia for reducing the risk of heart failure in patients with mildly reduced ejection fraction, a measure of how much blood the organ can pump. The daily pill was first approved in 2021 for patients with chronic kidney disease associated with type 2 diabetes. The post Bayer’s Blockbuster Hopeful Kerendia Expands its FDA Approval to Type of Heart Failure appeared first on MedCity News.

Finerenone Gets Expanded FDA Approval in Heart Failure

(MedPage Today) -- The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced. The nonsteroidal mineralocorticoid receptor antagonist (MRA) is the first of its class to win approval for treating...

Bayer gets sought-after heart failure use for Kerendia

Bayer's Kerendia has won FDA approval for a new heart failure indication thought to be pivotal for the product's blockbuster sales prospects.

Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Finerenone and the Future of Diabetes-Related Kidney Care

Finerenone emerges as a promising treatment for patients with diabetes and chronic kidney disease, significantly reducing cardiovascular and renal risks.